MAHEC Pain Presentation June 2011 · Author of this presentation does not have discloses concerning...
Transcript of MAHEC Pain Presentation June 2011 · Author of this presentation does not have discloses concerning...
5/30/2011
1
By: Traci Brooks, PharmDClinical Pharmacist
Womack Army Medical [email protected]
The views expressed herein are those of theauthor and do not reflect the official policyof the Department of the Army, Departmentof Defense, or the U.S. Government.
Author of this presentation does not havediscloses concerning possible financial orpersonal relationships with commercialentities that may have a direct or indirectinterest in the subject matter of thispresentation.
Conducting a Pain Assessment
What to do when starting chronic opioidtherapy
Review of Narcotic Analgesics◦ As needed medications
◦ Around the clock medications
Review of Odds and Ends
Urine Drug Screen information
Touch on Treating the Addicted Patient
5/30/2011
2
Chronic, painful conditions – 80 millionpeople in US◦ Millions undergo surgery or suffer a painful injury
1999 Gallup survey – 9 out of 10 Americansregularly suffer from pain.◦ 1 in 4 receive adequate pain treatment
2001 study – Geriatric patients frequentlyreceive inadequate pain therapy
February 1999 – VHA adds pain as a fifth vitalsign◦ JAMA 1995 article noted almost half of 10,000
dying patients included in this study died in severepain
2001 –Joint Commission implemented PainInitiative Standards
The New York Times – December 9, 2008◦ “The Pain May Be Real, but the Scan Is Deceiving”
◦ Scans are useful prior to surgical interventions.
◦ What you see on the scan may not be what iscausing the pain.
◦ What is causing the pain may correct itself withoutsurgical interventions.
History◦ Where is the pain?
5/30/2011
3
History◦ Where is the pain?
◦ How did the pain begin?
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
5/30/2011
4
Identify Acute or Chronic Pain
Chronic Pain◦ behavioral-psychological changes
◦ physiological changes within the nervous system
allodynia
hyperalgesia
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
Nocioceptive – localized, usually caused by aninjury
Neuropathic – more general area of pain◦ Central – phantom limb pain
◦ Peripheral – burning, tingling, numbness
Shooting
Prick
Ache
Burn
Throb
Pull
Sharp
Dull
Pattern of Pain Intermittent Constant
5/30/2011
5
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
◦ What is the pain intensity?
Advanced dementia
Intubated/unconscious patients
Infant and preverbal toddlers
Self reporting
Search for potential causes ofpain/discomfort
Observation of patient behavior
Surrogate reporting of pain
Attempt an analgesic trial
5/30/2011
6
Total scores range from 0 to 10 (based on a scale of 0 to 2 for five items),with a higher score indicating more severe pain (0=”no pain" to 10=”severepain”).
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
◦ What is the pain intensity?
◦ What improves the pain?
Medication
Eating
Rest
Sleep
Repositioning
Heat
Cold
Exercise
Relaxation
Massage
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
◦ What is the pain intensity?
◦ What improves the pain?
◦ Any relevant PMH?
5/30/2011
7
myocardial ischemia
neoplasm
expanding aortic aneurysm
diabetic neuropathy
AIDS
peripheral vascular disease
stroke
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
◦ What is the pain intensity?
◦ What improves the pain?
◦ Any relevant PMH?
◦ How does the pain impact your life?
Sleep
Mood
Activity
Nutrition
Elimination
Social Interactions
Self Image
Sexuality
History◦ Where is the pain?
◦ How did the pain begin?
◦ How long have you had the pain?
◦ Describe the pain.
◦ What is the pain intensity?
◦ What improves the pain?
◦ Any relevant PMH?
◦ How does the pain impact your life?
◦ What have you tried in the past?
5/30/2011
8
Medications◦ What medications have you taken?
◦ How did they work?
◦ Why did you stop taking it?
Surgical
Non-pharmacologic◦ Over-the-counter
◦ Alternative medicine
How do you prefer to take your painmedication?◦ Scheduled or PRN or Do not like taking medication
Do you feel you need a stronger painmedication?
Do you feel you need to take more of the painmedication than prescribed?
Are you concerned that you use too muchpain medication?
Waiting room
Rising from chair in waiting room
Gait walking to exam room
Pain behaviors throughout exam
General appearance
5/30/2011
9
Evaluated in person prior to initiation oftherapy◦ Including appropriate H&P
Assess risk factors for addiction/abuse◦ Family history of substance abuse, pending
legal/disciplinary actions related to controlledsubstances, certain psychiatric comorbidites, hx ofnoncompliance
Provide patient with risks/benefits/sideeffects associated with opioid use
Reassess at regular intervals
5 Questions to ask:◦ Is there a clear diagnosis?
◦ Is there documentation of adequate work-up?
◦ Is there functional impairment?
◦ Has non-opioid multi-modality treatment failed?
◦ Are there contraindications to opioid therapy?
Diagnosis◦ 1=benign chronic condition w/ min objective findings or
no definite medical diagnosis◦ 2=slowly progressive condition concordant w/ moderate
pain, or fixed condition w/ moderate objective findings◦ 3=advanced condition concordant w/ severe pain w/
objective findings
Intractability◦ 1=few therapies have been tried and the patient takes a
passive role in his/her pain management process◦ 2=most customary treatments have been tried but the
patient is not fully engaged, or barriers present◦ 3=patient fully engaged in a spectrum of appropriate
treatments but with inadequate response
Risk (R=total of P+C+R+S below)◦ Psychological
1=serious personality dysfunction or mental illnessinterfering with care
2=personality or mental health interferes moderately
3=good communication with clinic. No significantpersonality dysfunction
◦ Chemical Health
1=active or very recent use of illicit drugs, excessivealcohol, or prescription drug abuse
2=chemical coper or history of
3=Not drug-focused or chemically reliant
5/30/2011
10
Risk – continued◦ Reliability 1=history of numerous problems: medication misuse,
missed appts, rare follow through 2=occasional difficulties w/ compliance, generally reliable 3=highly reliable
◦ Social Support 1=life in chaos 2=reduction in some relationships, life roles 3=supportive family/close relationships
Efficacy score 1=poor function or minimal pain relief despite moderate to
high doses 2=moderate benefit w/ function improved 3=good improvement in pain, function and quality of life
Total score = D + I + R + E
Score 7-13: Not a suitable candidate forlong-term opioid analgesia
Score 14-21: Good candidate for long-termopioid analgesia
Meet with prescribing provider at least every60 to 90 days◦ High risk patients may warrant shorter intervals for
follow up
Agreement rather than contract
Clarifies expectations and responsibilities ofpatient and provider
Identify patient’s support system that arepermitted to discuss issues associated withpain management
Address sole provider prescribing,random/regular lab screenings, contingenciesfor non-compliance
5/30/2011
11
Random pill counts
Urine or blood screening
Discussion with family members
Per agreement – non-compliance may resultin transition to non-opioid treatment model
May include case management, clinicalpharmacy, pain management, primary care,behavioral health, physical therapy, socialwork, other specialists as needed(neurologist, oncologist)
North Carolina Controlled SubstancesRegistery
http://www.who.int/topics/en/
5/30/2011
12
Cancer pain
Terminally ill patients
Not Chronic Non-malignant Pain◦ Only when all conservative methods have been
exhausted
Safety◦ Respiratory depression
Tolerability◦ Itching, constipation, addiction
Efficacy◦ Reduction in pain score
Price
Simplicity
Phenanthrene
codeine
morphine
hydromorphone
oxymorphone
hydrocodone
oxycodone
Phenylpiperidines
◦ meperidine
◦ fentanyl
◦ sufentail
Diphenylheptanes◦ methadone
◦ propoxyphene
5/30/2011
13
Supraspinal analgesia
Respiratory depression
Euphoria
Physical Dependence
Decreased GI motility
Increased prolactinrelease
Miosis
Bradycardia
Spinal analgesia
Increased GH release
Inhibits Ach release
Spinal analgesia
Sedation
Disorientation,hallucinations
Depersonalization
Less miosis
Dysphoria
ADH release (diuresis)
Supraspinal analgesia
Positive reinforcement of supraspinalanalgesia
Suppresses noxious thermal stimuli atspinal cord
Enhances m agonists.
Hypersensitivity Severe respiratory depression Acute or severe asthma
Known or suspected paralytic ileus Head injury or carniotomy Acute pancreatitis Acute alcohol intoxication Hypovolemic shock – use IV
Hypothyroidism Convulsive Disorder Hepatic failure
5/30/2011
14
Starts after the first dose of opiate but is notclinically important until 2-3 weeks oftreatment
Minimized by administering opiates in smalldoses with long time intervals between doses
Develops to analgesic, respiratory andsedating effects but not to miosis,constipation and pruritis
Reversible and dissipates over time withdiscontinuation
CII◦ Morphine◦ Hydromorphone◦ Meperidine◦ Oxycodone◦ Fentanyl◦ Oxymorphone◦ Methadone◦ Tapentadol
CIII◦ Hydrocodone◦ Tylenol with codeine
CIV◦ Darvocet
Non-controlled◦ Tramadol
Natural opioid product
PO, PR, IV, SQ
Tolerance except to miosis and constipation
Metabolized hepatically with metabolitescleared renally
Drug of choice for MI pain due to decreasemyocardial oxygen demand
5/30/2011
15
Tablets: 10mg, 15mg, 30mg
Oral Solution: 10mg/5mL, 20mg/5mL,20mg/mL
Suppositories: 5mg, 10mg, 20mg, 30mg
Opioid naïve – 10mg PO q3-4h PRN
Time to onset – 30 minutes
Half-life (immediate release formulations) –2-4 hours
Semi-synthetic product
9 times more potent than morphine
PO, PR, IV, SQ
Possibly less constipation
Tolerance and physical dependence is moreintense than morphine
Hepatically metabolized to inactivemetabolites
Tablets: 1mg, 2mg, 3mg, 4mg, 8mg
Liquid: 5mg/5mL
Dosing (opioid naïve) – 2-4mg Q3-4h PRN
Time to onset – 15-30 minutes
Half-life – 1-3 hours
5/30/2011
16
2003 American Pain Society recommendednot using◦ For more than 48 hours
◦ In doses greater than 600mg/24hours
◦ In patients with pre-existing CNS or renaldysfunction
2007 Institute for Safe Medication Practicerecommends◦ Avoiding use in pain control
Semi-synthetic product
Only PO route
Hepatic metabolism via CYP 3A4 and 2D6
Many formulations with adjuvants
Percodan – oxycodone/aspirin
Percocet – oxycodone/acetaminophen
With adjuvant – Percocet: 2.5mg/325mg,5mg/325mg, 7.5mg/325mg, 7.5mg/500mg,10mg/325mg, 10mg/650mg
Without adjuvant◦ Tablets: 5mg, 15mg, 30mg
◦ Capsules: 5mg
Oral Solution: 5mg/5mL, 20mg/mL
New guidelines from FDA◦ Limiting amount of acetaminophen in combination
products not to exceed 325mg/tablet
Maximum dose per day◦ Acute use: no more than 4000mg/day
◦ Chronic use: leaning towards lower dose 2000-2600mg/day
5/30/2011
17
Opioid naïve (immediate release) – 5mg q6hPRN
Time to onset: 10-15 minutes
Half-life: 2-3 hours
Semi-synthetic product – similar chemicallyto hydromorphone
PO, IV, SC
Hepatic glucuronidation to active and inactivemetabolites
Products:◦ Immediate release: Opana 5mg, 10mg
Opioid naïve (immediate release) – 10-20mgq4-6h PRN◦ Administer 1 hour before or 2 hours after eating
Time to onset: Parenteral 5-10 minutes
Half-life: immediate release – 7-9hours;extended release – 9-11hours
Buccal film (Onsolis), Buccal tablet (Fentora),Lozenge (Actiq)
Only indicated for breakthrough cancer pain
Cannot convert on mcg/mcg basis from oneoral fentanyl product to another
5/30/2011
18
Time to peak:◦ Buccal film – 0.75-4 hours (median: 1hour)◦ Buccal tablet – 20-240 minutes (median:
47minutes)◦ Lozenge – 20-480 minutes (median: 20-40minutes)
Half-life:◦ Buccal film – 14hours◦ Buccal tablet 100-200mcg – 3-4hours
400-800mcg – 11-12hours
◦ Lozenge – 7hours
T #2 – 15mg of Codeine, 300mg Acetaminophen
T #3 – 30mg of Codeine, 300mg Acetaminophen
T #4 – 60mg of Codeine, 300mg Acetaminophen
Codeine is metabolized hepatically tomorphine via CYP2D6◦ Approximately 10% of Europeans and Caucasian
lack this ability
Opioid naïve – base off the codeinecomponent◦ 1-2 q4h PRN
Time to onset: 0.5 to 1 hour
Half-life: 2.5-3.5 hours
Derivative of codeine Many formulations with adjuvants◦ Lorcet – 10mg hydrocodone/650mg acetaminophen◦ Lorcet HD/Vicodin – 5mg/500mg◦ Lorcet Plus – 7.5mg/650mg◦ Lortab – 2.5mg/500mg, 5mg/500mg, 7.5mg/500mg,
10mg/500mg◦ Lortab elixir – 2.5mg/167mg per 5mL◦ Norco – 5/325mg, 7.5/325mg, 10/325mg◦ Vicodin ES – 7.5/750mg◦ Vicodin HP – 10/660mg
◦ Vicoprofen – 7.5mg hydrocodone/200mg ibuprofen
5/30/2011
19
Opioid naïve – 5-10mg four times daily ofhydrocodone◦ Limit acetaminophen consumption not to exceed
4000mg/day
Time to onset: 10-20 minutes
Half-life: 3.3-4.4 hours
18 times less potent than morphine in binding tomu-opioid receptors; 2-3 times less analgesiceffect
Binds to mu-opioid receptors, inhibits reuptakeof norepinephrine
Only oral route Drug/drug interaction with risk of serotonin
syndrome
Approved for acute pain not chronic use
Products:◦ Nucynta 50mg, 75mg, and 100mg◦ CII
Initial dose (acute mod/sev pain): 50-100mgq4-6h PRN (may administer 2nd dose morethan 1 hour after initial dose on day one only(maximum daily dose day 1=700mg;thereafter=600mg)
Half-life: 4 hours
Metabolized to norpropoxyphene (activemetabolite)◦ Long half-life of metabolite = accumulation
◦ Increase CNS side effects
Not recommended in geriatrics – Beer’scriteria
Naproxen has been shown to be superior toDarvocet with fewer side effects
FDA recommended to stop production anddistribution of Darvocet
5/30/2011
20
Mu receptor agonist; inhibits norepinephrineand serotonin reuptake
Drug interactions◦ SSRIs, TCAs, cyclobenzaprine, alcohol
Serotonin Syndrome
May lower seizure threshold
Regular release = 50mg
Extended release = 100mg, 200mg, 300mg
Gold Standard
Tablets:◦ MSContin: 15mg, 30mg, 60mg, 100mg, 200mg◦ Dose q8h or q12h – NEVER PRN
Capsules: May be opened and sprinkled onapplesauce◦ Kadian: 20mg, 30mg, 50mg, 60mg, 80mg, 100mg,
200mg Dose q12h or q24h
◦ Avinza: 30mg, 60mg, 90mg, 120mg Dose q24h
New sustainedrelease product
Dosing: Daily Doses: 8mg, 12mg,
16mg Half-life: ~11 hours Titrate no sooner
than every 3 days Administer no more
frequently thenevery 24 hours
Hydromorphone (Exalgo(ExalgoTMTM))
5/30/2011
21
Only if Morphine Sustained-Release fails◦ Exception – allergy to morphine, cancer pain
OxyContin -10mg, 20mg, 40mg, 60mg,80mg, 160mg◦ Dose q12h – NEVER PRN
◦ Can use different strengths to obtain same dose
New formulation approved Spring 2010◦ Due to abuse potential of original formulation
Reformulated tablets contain polyethyleneoxide◦ Insoluble in alcohols and upon contact with water it
forms a viscous gel.
Harder to cut, chew, break or crush◦ They either do not break or break into pieces that
retain some controlled-release functionality.
The imprint of the new tablets has an “OP”rather than “OC.”
Opioid naïve: 5mg q12h and supplement withoxymorphone immediate release◦ Adjust by 5-10mg every 12hours at interval of
every 3-7 days
5/30/2011
22
Synthetic product
80 to 100 times more potent than morphine
IV, transdermal, transmucosal
Hepatic metabolism via CYP3A4 to inactivemetabolites
Only for opioid tolerant patients with chronicstable pain
Opioid tolerancedefined:◦ Taking, for 7 days or
longer, at least 60mgof oral morphineequivalents daily
◦ Approximately 17hours after patchremoval serumconcentrations are at50% of their originalvalue
Transdermal Patch – 12.5mcg/hr, 25mcg/hr,50mcg/hr, 75mcg/hr, 100mcg/hr
Dose adjustments no sooner than every 3 days
Time to onset: 8 hours
Half-life:17 hours
Need special licensing to prescribemethadone for opioid detoxification but notfor pain management
Synthetic product
Multiple sites of receptor activity◦ Mu, kappa, delta, NMDA, inhibits NE and 5HT
Role in neuropathic pain…
5/30/2011
23
Pros:◦ Lack neuroactive
metabolites
◦ Good oralbioavailability
◦ Inexpensive
◦ Long duration ofactivity
◦ Less tolerance
Cons:◦ Overdose difficult to
treat◦ QTc prolongation◦ Social stigma◦ Long duration of
activity◦ Multiple methods of
conversions◦ “Catch-22” of
prescribing◦ Providers have little
experience withproper dosing
Is ONLY a SCREENING TOOL!!!
A positive result on UDS is not a confirmedpositive.
Many medications may cause a false positive.
A confirmation with GasChromatography/Mass Spectrometry isneeded
What tests to order?◦ Urine vs. Blood?
Urine – less invasive, remains in urine longer thanblood
◦ UDS
Screens for amphetamines, cannabinoids,benzodiazepines and opiates (morphine, codeine,cocaine, hydrocodone, heroin)
Random vs. Scheduled?
5/30/2011
24
Amphetamines Barbituates Benzodiazepines Cocaine Tetrahydrocannabinol Opiates – morphine derivatives Phencyclidine Propoxyphene
Bowel regimen◦ Constipation is inevitable with chronic opioid use
◦ Stool softener scheduled and stimulant laxative asneeded
Docusate 100mg twice daily; Bisacodyl 10mg twicedaily as needed for constipation
Miralax 17grams mixed with 8oz of water/juice daily
Nausea◦ Usually transient in nature (3-5 days)
◦ Prochlorperazine, promethazine, ondansetron
Sedation◦ Transient
◦ May decrease dose of opioid (add adjuvant)
Add short course of psychostimulant(Methylphenidate)
Myoclonus◦ High dose/renal impairment
◦ Opioid rotation
Pruritis◦ Common side effect – NOT an allergy
◦ Antihistamines
Adjuvant medications◦ Neuropathic pain medications
TCAs, gabapeninoids, anticonvulsants
◦ NSAIDs/COX II inhibitors
Naproxen, indomethacin, ibuprofen, celecoxib,meloxicam
◦ Steroids
Prednisone, dexamethasone
5/30/2011
25
Use equilanalgesic chart (next slide)
Rule of thumb: Round down when switchingopioids to account for cross-tolerance◦ 1/2 to 3/4 of total daily dose scheduled
Provide rescue/breakthrough medications◦ Appropriate intervals – typically q4h PRN based on
half-lives
Use PRNs to assist with dose titrations
Drug PO (mg) IV (mg)
Morphine 30 10
Hydromorphone 7.5 1.5
Oxycodone 20 NA
Hydrocodone 30 NA
Codeine 200 NA
Meperidine 300 100
Oxymorphone 10 1
Fentanyl NA 0.1
Tramadol 120 NA
Methadone consult
True allergies are rare – anaphylaxis
If patient has an allergy:◦ Determine reaction experienced
◦ Medications they have had success with since
Allergy to OxyContin but OK with Percocet?!?
◦ Document
5/30/2011
26
Symptomatic treatment◦ Clonidine, ondansetrone/phenergan, sleep aid,
anxiolytic
Methadone treatment◦ Requires FDA approved methadone clinics
Suboxone treatment◦ Requires provider to obtain DEA-X# for prescribing
for detoxification purposes
By: Traci Brooks, PharmDClinical Pharmacist
Womack Army Medical [email protected]